Midterm results of prostaglandin e1 treatment in patients with lumbar spinal canal stenosis accompanied by intermittent claudication

Kazuo Nakanishi, Masato Tanaka, Haruo Misawa, Tomoyuki Takigawa, Toshihumi Ozaki

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Study design.: The midterm results of prostaglandin E1 (PGE1) treatment in patients with lumbar spinal canal stenosis, and discuss the factors influencing the improvement rate by using multivariable analysis. Objective.: We report the clinical results of PGE1 treatments in patients with lumbar spinal canal stenosis. Summary of background data.: Neurogenic intermittent claudication, a prominent symptom of lumbar spinal canal stenosis, poses a substantial impairment of quality of life in patients. A variety of approaches to treatment for lumbar spinal canal stenosis have been reported. However, general systemic complications make it difficult for many elderly people to undergo surgical treatment. Sometimes the only reasonable option is to receive conservative treatment. Methods.: The subjects were 63 patients with lumbar spinal canal stenosis. After admission, patients were given an intravenous infusion of PGE1 (60 μg/d) for approximately 2 weeks. To obtain the spinal canal stenosis rate, the area of the dural canal observed on magnetic resonance imaging and CT myelography was measured by using image analysis software (NIH image). The correlation of improvement rates to ages, JOA scores, claudication distances, and stenosis rate obtained through magnetic resonance imaging was evaluated using multivariable analysis. Results.: Regardless of stenosis type, JOA scores significantly improved after PGE1 administration (the mixed type: P <0.0001, the nerve root type: P <0.01, and the cauda equina type: P <0.01), and claudication distance was significantly improved. Multivariable analysis showed that JOA scores before PGE1 administration significantly contributed to the improvement rates. Conclusion.: Our midterm results showed that PGE1 was useful for treating intermittent claudication in patients with lumbar spinal canal stenosis. The effect of PGE1 was not related to the degree of stenosis obtained with images, age, or claudication distance, but was correlated with baseline disease severity (JOA scores before administration).

Original languageEnglish
Pages (from-to)1465-1469
Number of pages5
JournalSpine
Volume33
Issue number13
DOIs
Publication statusPublished - Jun 1 2008

Fingerprint

Spinal Stenosis
Intermittent Claudication
Spinal Canal
Alprostadil
Pathologic Constriction
Therapeutics
Magnetic Resonance Imaging
Cauda Equina
Myelography
Intravenous Infusions
Software
Quality of Life

Keywords

  • Intermittent claudication
  • Lumbar canal stenosis
  • Prostaglandin E

ASJC Scopus subject areas

  • Clinical Neurology
  • Orthopedics and Sports Medicine
  • Physiology

Cite this

Midterm results of prostaglandin e1 treatment in patients with lumbar spinal canal stenosis accompanied by intermittent claudication. / Nakanishi, Kazuo; Tanaka, Masato; Misawa, Haruo; Takigawa, Tomoyuki; Ozaki, Toshihumi.

In: Spine, Vol. 33, No. 13, 01.06.2008, p. 1465-1469.

Research output: Contribution to journalArticle

@article{ecce43230bb74ab9a504cd6f114db3c2,
title = "Midterm results of prostaglandin e1 treatment in patients with lumbar spinal canal stenosis accompanied by intermittent claudication",
abstract = "Study design.: The midterm results of prostaglandin E1 (PGE1) treatment in patients with lumbar spinal canal stenosis, and discuss the factors influencing the improvement rate by using multivariable analysis. Objective.: We report the clinical results of PGE1 treatments in patients with lumbar spinal canal stenosis. Summary of background data.: Neurogenic intermittent claudication, a prominent symptom of lumbar spinal canal stenosis, poses a substantial impairment of quality of life in patients. A variety of approaches to treatment for lumbar spinal canal stenosis have been reported. However, general systemic complications make it difficult for many elderly people to undergo surgical treatment. Sometimes the only reasonable option is to receive conservative treatment. Methods.: The subjects were 63 patients with lumbar spinal canal stenosis. After admission, patients were given an intravenous infusion of PGE1 (60 μg/d) for approximately 2 weeks. To obtain the spinal canal stenosis rate, the area of the dural canal observed on magnetic resonance imaging and CT myelography was measured by using image analysis software (NIH image). The correlation of improvement rates to ages, JOA scores, claudication distances, and stenosis rate obtained through magnetic resonance imaging was evaluated using multivariable analysis. Results.: Regardless of stenosis type, JOA scores significantly improved after PGE1 administration (the mixed type: P <0.0001, the nerve root type: P <0.01, and the cauda equina type: P <0.01), and claudication distance was significantly improved. Multivariable analysis showed that JOA scores before PGE1 administration significantly contributed to the improvement rates. Conclusion.: Our midterm results showed that PGE1 was useful for treating intermittent claudication in patients with lumbar spinal canal stenosis. The effect of PGE1 was not related to the degree of stenosis obtained with images, age, or claudication distance, but was correlated with baseline disease severity (JOA scores before administration).",
keywords = "Intermittent claudication, Lumbar canal stenosis, Prostaglandin E",
author = "Kazuo Nakanishi and Masato Tanaka and Haruo Misawa and Tomoyuki Takigawa and Toshihumi Ozaki",
year = "2008",
month = "6",
day = "1",
doi = "10.1097/BRS.0b013e3181753c1e",
language = "English",
volume = "33",
pages = "1465--1469",
journal = "Spine",
issn = "0362-2436",
publisher = "Lippincott Williams and Wilkins",
number = "13",

}

TY - JOUR

T1 - Midterm results of prostaglandin e1 treatment in patients with lumbar spinal canal stenosis accompanied by intermittent claudication

AU - Nakanishi, Kazuo

AU - Tanaka, Masato

AU - Misawa, Haruo

AU - Takigawa, Tomoyuki

AU - Ozaki, Toshihumi

PY - 2008/6/1

Y1 - 2008/6/1

N2 - Study design.: The midterm results of prostaglandin E1 (PGE1) treatment in patients with lumbar spinal canal stenosis, and discuss the factors influencing the improvement rate by using multivariable analysis. Objective.: We report the clinical results of PGE1 treatments in patients with lumbar spinal canal stenosis. Summary of background data.: Neurogenic intermittent claudication, a prominent symptom of lumbar spinal canal stenosis, poses a substantial impairment of quality of life in patients. A variety of approaches to treatment for lumbar spinal canal stenosis have been reported. However, general systemic complications make it difficult for many elderly people to undergo surgical treatment. Sometimes the only reasonable option is to receive conservative treatment. Methods.: The subjects were 63 patients with lumbar spinal canal stenosis. After admission, patients were given an intravenous infusion of PGE1 (60 μg/d) for approximately 2 weeks. To obtain the spinal canal stenosis rate, the area of the dural canal observed on magnetic resonance imaging and CT myelography was measured by using image analysis software (NIH image). The correlation of improvement rates to ages, JOA scores, claudication distances, and stenosis rate obtained through magnetic resonance imaging was evaluated using multivariable analysis. Results.: Regardless of stenosis type, JOA scores significantly improved after PGE1 administration (the mixed type: P <0.0001, the nerve root type: P <0.01, and the cauda equina type: P <0.01), and claudication distance was significantly improved. Multivariable analysis showed that JOA scores before PGE1 administration significantly contributed to the improvement rates. Conclusion.: Our midterm results showed that PGE1 was useful for treating intermittent claudication in patients with lumbar spinal canal stenosis. The effect of PGE1 was not related to the degree of stenosis obtained with images, age, or claudication distance, but was correlated with baseline disease severity (JOA scores before administration).

AB - Study design.: The midterm results of prostaglandin E1 (PGE1) treatment in patients with lumbar spinal canal stenosis, and discuss the factors influencing the improvement rate by using multivariable analysis. Objective.: We report the clinical results of PGE1 treatments in patients with lumbar spinal canal stenosis. Summary of background data.: Neurogenic intermittent claudication, a prominent symptom of lumbar spinal canal stenosis, poses a substantial impairment of quality of life in patients. A variety of approaches to treatment for lumbar spinal canal stenosis have been reported. However, general systemic complications make it difficult for many elderly people to undergo surgical treatment. Sometimes the only reasonable option is to receive conservative treatment. Methods.: The subjects were 63 patients with lumbar spinal canal stenosis. After admission, patients were given an intravenous infusion of PGE1 (60 μg/d) for approximately 2 weeks. To obtain the spinal canal stenosis rate, the area of the dural canal observed on magnetic resonance imaging and CT myelography was measured by using image analysis software (NIH image). The correlation of improvement rates to ages, JOA scores, claudication distances, and stenosis rate obtained through magnetic resonance imaging was evaluated using multivariable analysis. Results.: Regardless of stenosis type, JOA scores significantly improved after PGE1 administration (the mixed type: P <0.0001, the nerve root type: P <0.01, and the cauda equina type: P <0.01), and claudication distance was significantly improved. Multivariable analysis showed that JOA scores before PGE1 administration significantly contributed to the improvement rates. Conclusion.: Our midterm results showed that PGE1 was useful for treating intermittent claudication in patients with lumbar spinal canal stenosis. The effect of PGE1 was not related to the degree of stenosis obtained with images, age, or claudication distance, but was correlated with baseline disease severity (JOA scores before administration).

KW - Intermittent claudication

KW - Lumbar canal stenosis

KW - Prostaglandin E

UR - http://www.scopus.com/inward/record.url?scp=46749140921&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=46749140921&partnerID=8YFLogxK

U2 - 10.1097/BRS.0b013e3181753c1e

DO - 10.1097/BRS.0b013e3181753c1e

M3 - Article

C2 - 18520942

AN - SCOPUS:46749140921

VL - 33

SP - 1465

EP - 1469

JO - Spine

JF - Spine

SN - 0362-2436

IS - 13

ER -